Pertuzumab–Docetaxel–Trastuzumab regimen in HER2-positive metastatic breast cancer: Real-world data from India

Purpose: Dual human epidermal growth factor receptor 2 (HER2) blockade with pertuzumab and trastuzumab plus chemotherapy is the standard first-line treatment for HER2-positive metastatic breast cancer (BC), as per the CLEOPATRA trial. However, real-world data from low- and middle-income countries (L...

Cijeli opis

Bibliografski detalji

Glavni autori:	Ajay Gogia, Atul Batra, Ashutosh Mishra, Kamal Kataria, Surendra K Saini, Sandeep Mathur, Chandra P Prasad, Hari Krishna Raju Sagiraju
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-01-01
Serija:	Cancer Treatment and Research Communications
Teme:	HER2-positive Metastatic breast cancer Adjuvant therapy PTH regimen Progression-free survival overall survival
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2468294226001073
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!